Skip to content

WHWK WHWK Stock-Based Comp

Stock-Based Comp at other companies

Eli Lilly logo
Eli LillyLLY
$161M+4.5%
Pfizer logo
PfizerPFE
$272M+60.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$257.4M+0.7%
Gilead Sciences logo
Gilead SciencesGILD
$218M+4.3%
AbbVie logo
AbbVieABBV
$444M+8.3%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$14.54M+42.0%

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's stock-based comp?
WHWK (WHWK) reported stock-based comp of $2.19M in Q1 2026.
How has WHWK's stock-based comp changed year-over-year?
WHWK's stock-based comp increased by 30.5% year-over-year, from $1.68M to $2.19M.
What is the long-term trend for WHWK's stock-based comp?
Over 3 years (2021 to 2025), WHWK's stock-based comp has grown at a 67.4% compound annual growth rate (CAGR), from $2.11M to $9.87M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.